607 related articles for article (PubMed ID: 16026855)
1. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
2. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation.
Shin SM; Kim YH; Choi BK; Kwon PM; Lee HW; Kwon BS
J Leukoc Biol; 2007 Jun; 81(6):1455-65. PubMed ID: 17389581
[TBL] [Abstract][Full Text] [Related]
6. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
7. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
8. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
9. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice.
Katchar K; Kelly CP; Keates S; O'brien MJ; Keates AC
Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1263-71. PubMed ID: 17272517
[TBL] [Abstract][Full Text] [Related]
10. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
12. Ameliorating effect of saporin-conjugated anti-CD11b monoclonal antibody in a murine T-cell-mediated chronic colitis.
Kanai T; Uraushihara K; Totsuka T; Nemoto Y; Fujii R; Kawamura T; Makita S; Sawada D; Yagita H; Okumura K; Watanabe M
J Gastroenterol Hepatol; 2006 Jul; 21(7):1136-42. PubMed ID: 16824065
[TBL] [Abstract][Full Text] [Related]
13. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
14. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease.
Sun Y; Wu XX; Yin Y; Gong FY; Shen Y; Cai TT; Zhou XB; Wu XF; Xu Q
Biochem Pharmacol; 2010 Jan; 79(2):229-38. PubMed ID: 19698701
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells participate in 4-1BB-mediated suppression of experimental allergic conjunctivitis.
Sumi T; Ishida W; Mittler RS; Yagita H; Taguchi O; Fukushima A
Int Arch Allergy Immunol; 2009; 148(4):305-10. PubMed ID: 19001790
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
17. Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis.
Dan N; Kanai T; Totsuka T; Iiyama R; Yamazaki M; Sawada T; Miyata T; Yagita H; Okumura K; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2003 Oct; 285(4):G754-60. PubMed ID: 12969829
[TBL] [Abstract][Full Text] [Related]
18. 4-1 BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model.
Cho YS; Kwon B; Lee TH; Kim TB; Moon KA; La S; Lee J; Lee SD; Oh YM; Moon HB
Clin Exp Allergy; 2006 Mar; 36(3):377-85. PubMed ID: 16499650
[TBL] [Abstract][Full Text] [Related]
19. CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells.
Polte T; Jagemann A; Foell J; Mittler RS; Hansen G
Clin Exp Allergy; 2007 Sep; 37(9):1374-85. PubMed ID: 17845419
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
